linjc16/ctgov huggingface dataset:
High Flow Nasal Cannula to Prevent Deoxygenation During Induction of General Anesthesia in Cesarean Section

Study Overview
=================
Brief Summary
-----------------
Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) using high flow oxygen therapy for preoxygenation and oxygen supplementation during apnoea has shown promising results

Detailed Description
-----------------
Eeffective preoxygenation followed by apnoeic oxygenation enables anaesthesiologists to safely prolong the apnoea time which is the time (seconds) of apnea following preoxygenation and muscle relaxation before to peripheral oxygen saturations (SpO2) decreases by 2%.

Official Title
-----------------
A Prospective Randomized Study of High Flow Nasal Cannula to Prevent Deoxygenation During Induction of General Anesthesia in Cesarean Section

Conditions
-----------------
Hypoxic Brain Injury, Maternal Death

Intervention / Treatment
-----------------
* Other: F Group
* Other: H Group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant females Of American Society of Anesthesiologists (ASA) physical Status I and II For elective cesarean section under general anesthesia Exclusion Criteria: with room air saturation of <98% anticipated difficult airway anticipated obstetric risk factor or precious baby chronic obstructive pulmonary disease thyrotoxicosis pheochromocytoma hyperkalaemia significant cardiac illness

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: face mask group<br>Pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring. | Other: F Group<br>* In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.<br>* Other names: face mask;|
| Active Comparator: THRIVE group<br>High-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds. | Other: H Group<br>* In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.<br>* Other names: THRIVE;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measure the time of safe apnea | The apnea time will start from the onset of cessation of breathing as evidenced by a flat line in the capnogram with the absence of chest movements | 10 minutes after induction |
A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This research study is designed to look at whether the routine use of shave margins (by taking extra tissue at the time of partial mastectomy surgery) will reduce the chances of having positive surgical margins requiring another surgical procedure, and whether this affects the long-term chances of getting cancer back in your breast.

Official Title
-----------------
A Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: Shave margins
* Procedure: No Shave Margins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Breast cancer, stage 0-3, deemed a surgically appropriate candidate for partial mastectomy with planned procedure for the same. Women ≥ 18 years of age. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Patients who have received previous neoadjuvant chemotherapy Patients who require a total mastectomy Known metastatic breast cancer.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Shave Margins<br> | Procedure: Shave margins<br>* Partial mastectomy with shave margins.<br>|
| Active Comparator: No shave margins<br> | Procedure: No Shave Margins<br>* Partial mastectomy without shave margins.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optimal surgical treatment | To determine whether routine shave margins in breast cancer patients undergoing partial mastectomy will result in more optimal surgical treatment of breast cancer patients, as defined by reduced positive margin rates | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cosmesis | To determine the effect of routine shave margins on cosmesis | 12 months | 
| Operative time | To determine the effect of routine shave margins on the time in the operating suite. | 12 months | 
| Volume of tissue resected | To determine the effect of routine shave margins on the volume of tissue resected. | 12 months |
Patients Navigator for Organized Colorectal Cancer Screening

Study Overview
=================
Brief Summary
-----------------
The main objective is to evaluate the impact of the recruitment and training of a peer-navigator on the participation rate of colorectal cancer screening among underserved area. The role of the navigator is to establish an intervention culturally-tailored to the inhabitants in order to promote the Fecal Occult Blood test (FOBT) and accompany the inhabitants to complementary exams, if needed.

Official Title
-----------------
Patients Navigator for Organized Colorectal Cancer Screening in Underserved Population

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Navigator intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: person living in the IRIS intervention zones person invited by the local management structure to participate in colorectal cancer screening Exclusion Criteria: person not living in the IRIS intervention zone person not invited by the local management structure to participate to colorectal cancer screening

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention of navigators<br>Navigators accompany the target population towards OCCS. | Behavioral: Navigator intervention<br>* peers sharing common characteristics with the target population whose mission is to accompany towards OCCS<br>|
| No Intervention: No Intervention<br>Population is not accompanied by navigators | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participation rates | Participation rates between intervention areas and control areas before/after intervention | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients primary care peers take care of |  | 24 months | 
| Qualitative analysis | A questionnaire will be given to those contacted and some people will be interviewed | 1 hour |
Drain After Elective Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
The trial aims to assess the value of drains in elective laparoscopic cholecystectomy.

Detailed Description
-----------------
After laparoscopic gallbladder removal patients are randomized to have a suction drain positioned in the subhepatic space or to have a sham drain in the subhepatic space. The primary outcome measure will be the presence of subhepatic fluid collection at ultrasonographic examination on the first postoperative day. Secondary outcome measures will be postoperative abdominal and shoulder tip pain, use of analgesics, nausea, vomiting and morbidity

Official Title
-----------------
Drain After Elective Laparoscopic Cholecystectomy. A Randomized Controlled Trial

Conditions
-----------------
Cholelithiasis

Intervention / Treatment
-----------------
* Procedure: no drain
* Procedure: drain positioned
* Procedure: drain not positioned


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective laparoscopic cholecystectomy Exclusion Criteria: acute cholecystitis, cholangitis, or pancreatitis no contraindication for the laparoscopic no other additional procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: Absence of drain<br> | Procedure: no drain<br>* drain positioned on the skin<br>Procedure: drain not positioned<br>* Drain positioned in the abdominal wall<br>|
| Active Comparator: Drain<br>drain positioned in the subhepatic space after laparoscopic cholecystectomy | Procedure: drain positioned<br>* drain positioned in the subhepatic space<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Subhepatic Collection at Ultrasonographic Examination | An abdominal ultrasonography was routinely performed on the first postoperative day with the aim to detect any fluid collection. If present, the volume in ml of subhepatic collection was calculated. | first postoperative day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Postoperative Complications |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laparoscopy, cholecystectomy, drainage
Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine when a memory immune response after re-vaccination with Meningococcal C conjugate vaccine (Menjugate) or challenge with Meningococcal A/C polysaccharide vaccine can be observed, after initial vaccination with Meningococcal C conjugate vaccine during the UK immunization campaign

Official Title
-----------------
A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate®

Conditions
-----------------
Meningococcal Disease; Meningococcal Meningitis

Intervention / Treatment
-----------------
* Biological: · Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adolescents between and including 13-15 years of age, who provide written informed consent and who received one immunization with Chiron Meningococcal C Conjugate vaccine (Menjugate) during the UK immunization campaign and for which documentation can be provided. Exclusion Criteria: Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: · Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To measure immunological memory response to N. meningitidis serogroup C after those who received a partial dose of Meningococcal A/C Polysaccharide vaccine and in subjects who received a dose of Chiron Meningococcal C conjugate vaccine. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the immunological response to N. meningitidis serogroup C in those challenged with meningococcal A/C polysaccharide vaccine and in those who received a dose of Chiron Meningococcal C conjugate vaccine. |  |  |
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Official Title
-----------------
A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo.

Conditions
-----------------
Impetigo

Intervention / Treatment
-----------------
* Drug: SB-275833 ointment, 1%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Must have primary impetigo with total lesion area being 100 square centimeters or less. Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures. Exclusion Criteria: Any signs and symptoms of systemic infection. Any serious underlying disease that could be imminently life threatening.

Ages Eligible for Study
-----------------
Minimum Age: 9 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SB-275833 ointment, 1%|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical response of impetigo at end of therapy visit. Clinical response of success is defined as no further need for antibacterial treatment. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical response of impetigo at follow up visit. Impetigo lesion area at end of therapy and follow up visits. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
impetigo, topical antibacterial, topical antibiotic
Evaluation of PET CT in the Management of Patients With Crohn's Disease.

Study Overview
=================
Brief Summary
-----------------
18F-FDG PET/CT (2-[fluorine-18] fluoro-2-deoxy-D-glucose, Positron emission tomography- CT) is a noninvasive technique that allows quantifying and precisely localizing 18F-FDG uptake in the entire body. 18F-FDG uptake is caused by increased local metabolic activity. Such increased uptake has been described not only in neoplastic lesions but also in inflammatory lesions. In this condition, uptake has been correlated with local stimulation of tumor necrosis factor, and with monocyte priming and activation. A physiologic variable uptake may be observed in the bowel, especially the cecum, and has limited the use of PET in inflammatory bowel diseases. The advantage of combined PET and CT devices lead to significant improvements in the interpretation of the bowel areas, and greatly reduces the number of false-positive findings in the gastrointestinal tract.

Official Title
-----------------
Evaluation of PET CT in the Management of Patients With Crohn's Disease.

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Radiation: FDG PET CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suspicious for active disease: Patients with suspected but undiagnosed Crohn's disease Patients with serological markers of inflammation (elevated ESR, CRP or thrombocytosis) but clinically in remission Patients with a stricture which might be fibrous in which case surgery is indicated or inflammatory for which medical management is indicated Able to sign a consent form Exclusion Criteria: Pregnancy Breastfeeding Infectious colitis determined at the initial checkup Allergy to iodine contrast

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>PET CT | Radiation: FDG PET CT<br>* FDG PET CT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crohn's disease
A Randomized Multicenter Study of Daylight Mediated Photodynamic Therapy (PDT)

Study Overview
=================
Brief Summary
-----------------
A randomised, multi-center study of daylight mediated photodynamic therapy (PDT) with Metvix in patients with multiple actinic keratosis on the face and/or scalp.

Conditions
-----------------
Actinic Keratoses

Intervention / Treatment
-----------------
* Procedure: Photodynamic therapy with methyl aminolevulinate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older, 5 AK in face and scalp Exclusion Criteria: immunosuppression

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>2 hours sunlight | Procedure: Photodynamic therapy with methyl aminolevulinate<br>* daylight mediated photodynamic therapy<br>|
| Active Comparator: B<br>3 hours of sunlight | Procedure: Photodynamic therapy with methyl aminolevulinate<br>* daylight mediated photodynamic therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| response rate |  | 3 months |
The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm Infants

Study Overview
=================
Brief Summary
-----------------
The study aims to assess the incidence and the risk factors of nephrocalcinosis in very preterm infants using patient data collected during hospitalisation at the Neonatology Centre.

Detailed Description
-----------------
Nephrocalcinosis in preterm infants develops as a result of imbalance between the factors promoting or inhibiting formation of kidney stones. It is caused by intensive treatment as well as functional and morphological kidney immaturity. There is a correlation between the prevalence of nephrocalcinosis and low gestational age. The study aims prospectively to assess the incidence and the risk factors of nephrocalcinosis in very preterm infants less than 32 weeks of gestation.

Official Title
-----------------
The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm Infants at the Neonatology Centre of Vilnius University Hospital Santaros Klinikos

Conditions
-----------------
Nephrocalcinosis, Preterm Infant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: preterm infants of the gestational age of <32 weeks; parental consent acquired. Exclusion Criteria: death before 28 days of age; congenital defects; no kidney ultrasound results; no parental consent.

Ages Eligible for Study
-----------------
Minimum Age: 23 Weeks
Maximum Age: 31 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of nephrocalcinosis in very preterm infants less than 32 weeks of gestation | Kidney ultrasound results will divide preterm infants in the group with and without nephrocalcinosis (control). | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare demographic, clinical, biochemical and treatment results between nephrocalcinosis and the control (without nephrocalcinosis) groups. | Patients data (demographic, clinical, biochemical and treatment results) collected during hospitalisation at the Neonatology Centre will be compared between nephrocalcinosis and control group. | 3 years | 
| To evaluate the dynamics of nephrocalcinosis at 6 and 12 months of corrected age. | Nephrologist consultation of the infants with nephrocalcinosis at 6 and 12 months of corrected age | 6 and 12 months of corrected age |